Urokinase receptor

From Proteopedia

Revision as of 09:57, 8 April 2024 by Michal Harel (Talk | contribs)
(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)
Jump to: navigation, search

Caption for this structure(PDB code 2l9b)

Drag the structure with the mouse to rotate

References

  1. Nykjaer A, Møller B, Todd RF 3rd, Christensen T, Andreasen PA, Gliemann J, Petersen CM. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol. 1994 Jan 15;152(2):505-16 PMID:8283034
  2. Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, Zambrano N, Fontanini G, Servadio A, Pignataro G, Grumetto L, Lavecchia A, Bruzzese D, Iaccarino A, Troncone G, Veneziani BM, Montuori N, Placido S, Bianco R. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci Rep. 2017 Aug 24;7(1):9388. PMID:28839232 doi:10.1038/s41598-017-10062-1
  3. Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med. 2015 Nov 12;373(20):1916-25. PMID:26539835 doi:10.1056/NEJMoa1506362
  4. Zhai BT, Tian H, Sun J, Zou JB, Zhang XF, Cheng JX, Shi YJ, Fan Y, Guo DY. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J Transl Med. 2022 Mar 18;20(1):135. PMID:35303878 doi:10.1186/s12967-022-03329-3
  5. Gonias SL, Hu J. Urokinase receptor and resistance to targeted anticancer agents. Front Pharmacol. 2015 Jul 27;6:154. PMID:26283964 doi:10.3389/fphar.2015.00154

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky

Personal tools